Sofie H Tolmeijer
Overview
Explore the profile of Sofie H Tolmeijer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Wilpe S, Croci D, Fonseca Costa S, Te Paske I, Tolmeijer S, van Ipenburg J, et al.
JCI Insight
. 2025 Jan;
10(5).
PMID: 39883530
Background: Previously, we demonstrated that changes in circulating tumor DNA (ctDNA) are promising biomarkers for early response prediction (ERP) to immune checkpoint inhibitors (ICIs) in metastatic urothelial cancer (mUC). In...
2.
Wyatt A, Litiere S, Bidard F, Cabel L, Dyrskjot L, Karlovich C, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5034-5041.
PMID: 39269996
Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in...
3.
Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A, et al.
Nat Commun
. 2024 Feb;
15(1):1828.
PMID: 38418825
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification...
4.
Slootbeek P, Tolmeijer S, Mehra N, Schalken J
Crit Rev Clin Lab Sci
. 2023 Oct;
61(3):178-204.
PMID: 37882463
The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been fundamentally transformed by our greater understanding of its complex biological mechanisms and its entrance into the era of precision oncology....
5.
Tolmeijer S, van Wilpe S, Geerlings M, von Rhein D, Smilde T, Kloots I, et al.
Eur Urol Oncol
. 2023 Sep;
7(2):282-291.
PMID: 37673768
Background: Immune checkpoint inhibitors (ICIs) can induce durable disease control in metastatic urothelial cancer (mUC), but only 20-25% of patients respond. Early identification of a nondurable response will improve management...
6.
Tolmeijer S, Boerrigter E, Sumiyoshi T, Kwan E, Ng S, Annala M, et al.
Clin Cancer Res
. 2023 Mar;
29(15):2835-2844.
PMID: 36996325
Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is common. Early identification of resistance will improve management strategies....
7.
Hofste L, Geerlings M, von Rhein D, Tolmeijer S, Weiss M, Gilissen C, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139577
Patients diagnosed with locally advanced esophageal cancer are often treated with neoadjuvant chemoradiotherapy followed by surgery. This study explored whether detection of circulating tumor DNA (ctDNA) in plasma can be...
8.
Tolmeijer S, Boerrigter E, Schalken J, Geerlings M, van Oort I, van Erp N, et al.
JCO Precis Oncol
. 2022 Jan;
4:714-729.
PMID: 35050750
Purpose: It has been suggested that androgen receptor copy number gain ( gain) detected in cell-free DNA (cfDNA) can predict treatment response to androgen receptor signaling inhibitors (ARSIs) in patients...
9.
Tolmeijer S, Koornstra R, de Groot J, Geerlings M, van Rens D, Boers-Sonderen M, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359813
For patients with newly diagnosed metastatic melanoma, rapid BRAF mutation (mBRAF) assessment is vital to promptly initiate systemic therapy. Additionally, blood-based biomarkers are desired to monitor and predict treatment response....
10.
van Wilpe S, Tolmeijer S, Koornstra R, de Vries I, Gerritsen W, Ligtenberg M, et al.
Cancers (Basel)
. 2021 Jun;
13(9).
PMID: 34067105
Homologous recombination repair deficiency (HRD) can be observed in virtually all cancer types. Although HRD sensitizes tumors to DNA-damaging chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors, all patients ultimately develop resistance...